Publications by authors named "Jan Stetka"

Claim this Profile
L
Loss of Socs2 improves molecular responses to IFNα in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F.
Marc Usart, Quentin Kimmerlin, Jan Stetka, Cédric Stoll, Shivam Rai

Leukemia· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.
Marc Usart, Jan Stetka, Damien Luque Paz, Nils Hansen, Quentin Kimmerlin

Blood· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN.
Marc Usart, Nils Hansen, Jan Stetka, Tiago Almeida Fonseca, Alexandre Guy

Blood Adv· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms.
Damien Luque Paz, Michael S Bader, Ronny Nienhold, Shivam Rai, Tiago Almeida Fonseca, Jan Stetka

Hemasphere· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.
Jan Stetka, Marc Usart, Lucia Kubovcakova, Shivam Rai, Tata Nageswara Rao

Blood· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality.
Tata Nageswara Rao, Nils Hansen, Jan Stetka, Damien Luque Paz, Milena Kalmer

Blood· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34 Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients.
Pavla Koralkova, Monika Belickova, David Kundrat, Michaela Dostalova Merkerova, Zdenek Krejcik, Jan Stetka

Cancers (Basel)· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents.
Jan Stetka, Radek C Skoda

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes.
Jan Stetka, Jan Gursky, Julie Liñan Velasquez, Renata Mojzikova, Pavla Vyhlidalova

Cancers (Basel)· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis